The role of the PLA2G6 gene in neurodegenerative diseases

[1]  G. Abbruzzese,et al.  Long-Term Neuroradiological and Clinical Evaluation of NBIA Patients Treated with a Deferiprone Based Iron-Chelation Therapy , 2022, Journal of clinical medicine.

[2]  Bicheng Yang,et al.  Identification of a Novel Nonsense Mutation in PLA2G6 and Prenatal Diagnosis in a Chinese Family With Infantile Neuroaxonal Dystrophy , 2022, Frontiers in Neurology.

[3]  Babylakshmi Muthusamy,et al.  PLA2G6-associated neurodegeneration in four different populations-case series and literature review. , 2022, Parkinsonism & related disorders.

[4]  A. Lang,et al.  Nomenclature of Genetic Movement Disorders: Recommendations of the International Parkinson and Movement Disorder Society Task Force – An Update , 2022, Movement disorders : official journal of the Movement Disorder Society.

[5]  Hong-Fu Li,et al.  Clinical Characterization and Founder Effect Analysis in Chinese Patients with Phospholipase A2-Associated Neurodegeneration , 2022, Brain sciences.

[6]  G. Stevanin,et al.  Insights into Clinical, Genetic, and Pathological Aspects of Hereditary Spastic Paraplegias: A Comprehensive Overview , 2021, Frontiers in Molecular Biosciences.

[7]  J. Hardy,et al.  Dissecting the Phenotype and Genotype of PLA2G6‐Related Parkinsonism , 2021, Movement disorders : official journal of the Movement Disorder Society.

[8]  H. Deng,et al.  Human genetic basis of coronavirus disease 2019 , 2021, Signal Transduction and Targeted Therapy.

[9]  C. Crosio,et al.  Parkinson’s Disease-Related Genes and Lipid Alteration , 2021, International journal of molecular sciences.

[10]  D. Erskine,et al.  Insights into Lewy body disease from rare neurometabolic disorders , 2021, Journal of Neural Transmission.

[11]  R. Franco,et al.  Genes Implicated in Familial Parkinson’s Disease Provide a Dual Picture of Nigral Dopaminergic Neurodegeneration with Mitochondria Taking Center Stage , 2021, International journal of molecular sciences.

[12]  S. Schneider,et al.  Emerging Disease-Modifying Therapies in Neurodegeneration With Brain Iron Accumulation (NBIA) Disorders , 2021, Frontiers in Neurology.

[13]  Y. Shimo,et al.  PLA2G6 variants associated with the number of affected alleles in Parkinson’s disease in Japan , 2020, Neurobiology of Aging.

[14]  D. Hernandez,et al.  Genome-Wide Association Study Meta-Analysis for Parkinson’s Disease Motor Subtypes , 2020, bioRxiv.

[15]  C. Espinós,et al.  Mitochondrial Dysfunction, Oxidative Stress and Neuroinflammation in Neurodegeneration with Brain Iron Accumulation (NBIA) , 2020, Antioxidants.

[16]  K. Danzer,et al.  The Role of Lipids in the Initiation of α-Synuclein Misfolding , 2020, Frontiers in Cell and Developmental Biology.

[17]  R. Nashmi,et al.  Loss of tyrosine hydroxylase, motor deficits and elevated iron in a mouse model of phospholipase A2G6-associated neurodegeneration (PLAN) , 2020, Brain Research.

[18]  A. Cuadrado,et al.  Inflammation in Parkinson’s Disease: Mechanisms and Therapeutic Implications , 2020, Cells.

[19]  J. Jankovic,et al.  Parkinson’s disease: etiopathogenesis and treatment , 2020, Journal of Neurology, Neurosurgery, and Psychiatry.

[20]  H. Rideout,et al.  The Future of Targeted Gene-Based Treatment Strategies and Biomarkers in Parkinson’s Disease , 2020, Biomolecules.

[21]  D. Adams,et al.  The infantile neuroaxonal dystrophy rating scale (INAD-RS) , 2020, Orphanet Journal of Rare Diseases.

[22]  Pei-Lung Chen,et al.  Genotype-phenotype correlations of adult-onset PLA2G6-associated Neurodegeneration: case series and literature review , 2020, BMC Neurology.

[23]  N. Hattori,et al.  Parkinson’s disease-associated iPLA2-VIA/PLA2G6 regulates neuronal functions and α-synuclein stability through membrane remodeling , 2019, Proceedings of the National Academy of Sciences.

[24]  T. Huisman,et al.  PLA2G6-associated neurodegeneration: New insights into brain abnormalities and disease progression. , 2019, Parkinsonism & related disorders.

[25]  B. Tang,et al.  PLA2G6-Associated Neurodegeneration (PLAN): Review of Clinical Phenotypes and Genotypes , 2018, Front. Neurol..

[26]  S. Tsuji,et al.  PLA2G6-associated neurodegeneration presenting as a complicated form of hereditary spastic paraplegia , 2018, Journal of Human Genetics.

[27]  H. Bellen,et al.  Phospholipase PLA2G6, a Parkinsonism-Associated Gene, Affects Vps26 and Vps35, Retromer Function, and Ceramide Levels, Similar to α-Synuclein Gain. , 2018, Cell metabolism.

[28]  J. Jankovic,et al.  The Role of TMEM230 Gene in Parkinson’s Disease , 2018, Journal of Parkinson's disease.

[29]  P. Damier,et al.  PLA2G6-related parkinsonism presenting as adolescent behavior , 2018, Acta Neurologica Belgica.

[30]  F. Biagioni,et al.  Heterozygous PLA2G6 Mutation Leads to Iron Accumulation Within Basal Ganglia and Parkinson's Disease , 2018, Front. Neurol..

[31]  W. Ni,et al.  Novel PLA2G6 mutations and clinical heterogeneity in Chinese cases with phospholipase A2-associated neurodegeneration. , 2018, Parkinsonism & related disorders.

[32]  Peng Wang,et al.  The genetics of Parkinson disease , 2018, Ageing Research Reviews.

[33]  R. Gross,et al.  The structure of iPLA2β reveals dimeric active sites and suggests mechanisms of regulation and localization , 2018, Nature Communications.

[34]  E Ray Dorsey,et al.  The Parkinson Pandemic-A Call to Action. , 2018, JAMA neurology.

[35]  C. Paisán-Ruiz,et al.  Pla2g6 Deficiency in Zebrafish Leads to Dopaminergic Cell Death, Axonal Degeneration, Increased β-Synuclein Expression, and Defects in Brain Functions and Pathways , 2018, Molecular Neurobiology.

[36]  S. Lai,et al.  PARK14 PLA2G6 mutants are defective in preventing rotenone-induced mitochondrial dysfunction, ROS generation and activation of mitochondrial apoptotic pathway , 2017, Oncotarget.

[37]  R. Schüle,et al.  PLA2G6 mutations associated with a continuous clinical spectrum from neuroaxonal dystrophy to hereditary spastic paraplegia , 2017, Clinical genetics.

[38]  Dennis W Dickson,et al.  Pathology of Neurodegenerative Diseases. , 2017, Cold Spring Harbor perspectives in biology.

[39]  J. Volkmann,et al.  Parkinson disease , 2017, Nature Reviews Disease Primers.

[40]  Zhongsheng Sun,et al.  Identification of Novel Compound Mutations in PLA2G6-Associated Neurodegeneration Patient with Characteristic MRI Imaging , 2017, Molecular Neurobiology.

[41]  N. Hattori,et al.  Mutation screening of PLA2G6 in Japanese patients with early onset dystonia-parkinsonism , 2017, Journal of Neural Transmission.

[42]  J. Friedman,et al.  PLA2G6 mutations and Parkinsonism: Long‐term follow‐up of clinical features and neuropathology , 2016, Movement disorders : official journal of the Movement Disorder Society.

[43]  Y. Liu,et al.  Identification of a novel mutation in PLA2G6 gene in a Chinese pedigree with familial cortical myoclonic tremor with epilepsy , 2016, Seizure.

[44]  W. Halliday,et al.  Validation of the finding of hypertrophy of the clava in infantile neuroaxonal dystrophy/PLA2G6 by biometric analysis , 2016, Neuroradiology.

[45]  S. Bohlega,et al.  Clinical heterogeneity of PLA2G6-related Parkinsonism: analysis of two Saudi families , 2016, BMC Research Notes.

[46]  A. Mahadevan,et al.  Genetic Analysis of PLA2G6 in 22 Indian Families with Infantile Neuroaxonal Dystrophy, Atypical Late-Onset Neuroaxonal Dystrophy and Dystonia Parkinsonism Complex , 2016, PloS one.

[47]  A. Munnich,et al.  Utility of whole exome sequencing for the early diagnosis of pediatric-onset cerebellar atrophy associated with developmental delay in an inbred population , 2016, Orphanet Journal of Rare Diseases.

[48]  P. Heutink,et al.  PLA2G6 Mutations Related to Distinct Phenotypes: A New Case with Early-onset Parkinsonism , 2016, Tremor and other hyperkinetic movements.

[49]  M. Kirber,et al.  Impairment of PARK14-dependent Ca2+ signalling is a novel determinant of Parkinson's disease , 2016, Nature Communications.

[50]  C. Toro,et al.  Disruption of Golgi morphology and altered protein glycosylation in PLA2G6-associated neurodegeneration , 2015, Journal of Medical Genetics.

[51]  Christer S. Ejsing,et al.  The GARP complex is required for cellular sphingolipid homeostasis , 2015, eLife.

[52]  X. Lei,et al.  Calcium-independent phospholipases A2 and their roles in biological processes and diseases , 2015, Journal of Lipid Research.

[53]  J. Hardy,et al.  Loss of PLA2G6 leads to elevated mitochondrial lipid peroxidation and mitochondrial dysfunction , 2015, Brain : a journal of neurology.

[54]  C. Lyoo,et al.  Neuroimaging studies and whole exome sequencing of PLA2G6-associated neurodegeneration in a family with intrafamilial phenotypic heterogeneity. , 2015, Parkinsonism & related disorders.

[55]  Bale,et al.  Standards and Guidelines for the Interpretation of Sequence Variants: A Joint Consensus Recommendation of the American College of Medical Genetics and Genomics and the Association for Molecular Pathology , 2015, Genetics in Medicine.

[56]  N. Bresolin,et al.  A novel homozygous PLA2G6 mutation causes dystonia-parkinsonism. , 2015, Parkinsonism & related disorders.

[57]  Y. Bao,et al.  Genetic variants of PLA2G6 are associated with Type 2 diabetes mellitus and triglyceride levels in a Chinese population , 2015, Diabetic medicine : a journal of the British Diabetic Association.

[58]  C. Drissi,et al.  Infantile and childhood onset PLA2G6‐associated neurodegeneration in a large North African cohort , 2015, European journal of neurology.

[59]  S. Levi,et al.  Neurodegeneration with brain iron accumulation: update on pathogenic mechanisms , 2014, Front. Pharmacol..

[60]  M. Seven,et al.  Recessive truncating NALCN mutation in infantile neuroaxonal dystrophy with facial dysmorphism , 2013, Journal of Medical Genetics.

[61]  G. Sobue,et al.  Extensive aggregation of α-synuclein and tau in juvenile-onset neuroaxonal dystrophy: an autopsied individual with a novel mutation in the PLA2G6 gene-splicing site , 2013, Acta neuropathologica communications.

[62]  Y. Jiang,et al.  Follow‐up study of 25 Chinese children with PLA2G6‐associated neurodegeneration , 2013, European journal of neurology.

[63]  Hong‐Mei Liu,et al.  Four novel rare mutations of PLA2G6 in Chinese population with Parkinson's disease. , 2013, Parkinsonism & related disorders.

[64]  V. Sossi,et al.  Imaging striatal dopaminergic function in Phospholipase A2 Group VI–related parkinsonism , 2012, Movement disorders : official journal of the Movement Disorder Society.

[65]  B. Tang,et al.  Analysis of PLA2G6 gene mutation in sporadic early-onset parkinsonism patients from Chinese population , 2012, Neuroscience Letters.

[66]  J. Hardy,et al.  Widespread Lewy body and tau accumulation in childhood and adult onset dystonia-parkinsonism cases with PLA2G6 mutations , 2012, Neurobiology of Aging.

[67]  Rou-shayn Chen,et al.  PLA2G6 mutations in PARK14‐linked young‐onset parkinsonism and sporadic Parkinson's disease , 2012, American journal of medical genetics. Part B, Neuropsychiatric genetics : the official publication of the International Society of Psychiatric Genetics.

[68]  Zhongming Ma,et al.  Genetic Ablation of PLA2G6 in Mice Leads to Cerebellar Atrophy Characterized by Purkinje Cell Loss and Glial Cell Activation , 2011, PloS one.

[69]  K. Xia,et al.  PLA2G6 gene mutation in autosomal recessive early-onset parkinsonism in a Chinese cohort , 2011, Neurology.

[70]  N. Bresolin,et al.  Novel splice‐site mutations and a large intragenic deletion in PLA2G6 associated with a severe and rapidly progressive form of infantile neuroaxonal dystrophy , 2010, Clinical genetics.

[71]  P. Kotzbauer,et al.  Catalytic Function of PLA2G6 Is Impaired by Mutations Associated with Infantile Neuroaxonal Dystrophy but Not Dystonia-Parkinsonism , 2010, PloS one.

[72]  A. Singleton,et al.  Early‐onset L‐dopa‐responsive parkinsonism with pyramidal signs due to ATP13A2, PLA2G6, FBXO7 and spatacsin mutations , 2010, Movement disorders : official journal of the Movement Disorder Society.

[73]  M. Kurian,et al.  Multiplex ligation-dependent probe amplification (MLPA) analysis is an effective tool for the detection of novel intragenic PLA2G6 mutations: implications for molecular diagnosis. , 2010, Molecular genetics and metabolism.

[74]  E. Elahi,et al.  R632W mutation in PLA2G6 segregates with dystonia‐parkinsonism in a consanguineous Iranian family , 2009, European journal of neurology.

[75]  D. Hernandez,et al.  Characterization of PLA2G6 as a locus for dystonia‐parkinsonism , 2008, Annals of neurology.

[76]  E. Bertini,et al.  Neurodegeneration associated with genetic defects in phospholipase A2 , 2008, Neurology.

[77]  J. Morton,et al.  Phenotypic spectrum of neurodegeneration associated with mutations in the PLA2G6 gene (PLAN) , 2008, Neurology.

[78]  S. Sakoda,et al.  Neuroaxonal Dystrophy Caused by Group VIA Phospholipase A2 Deficiency in Mice: A Model of Human Neurodegenerative Disease , 2008, The Journal of Neuroscience.

[79]  Colin A. Johnson,et al.  PLA2G6, encoding a phospholipase A2, is mutated in neurodegenerative disorders with high brain iron , 2006, Nature Genetics.

[80]  J. Balsinde,et al.  Cellular regulation and proposed biological functions of group VIA calcium-independent phospholipase A2 in activated cells. , 2005, Cellular signalling.

[81]  A. Gregory,et al.  Neurodegeneration with brain iron accumulation. , 2005, Folia neuropathologica.

[82]  J. Turk,et al.  The expression and function of a group VIA calcium-independent phospholipase A2 (iPLA2β) in β-cells , 2004 .

[83]  B. Kennedy,et al.  The human calcium-independent phospholipase A2 gene multiple enzymes with distinct properties from a single gene. , 1999, European journal of biochemistry.

[84]  B. Kennedy,et al.  Multiple Splice Variants of the Human Calcium-independent Phospholipase A2 and Their Effect on Enzyme Activity* , 1998, The Journal of Biological Chemistry.

[85]  J. Balsinde,et al.  Identity between the Ca2+-independent Phospholipase A2 Enzymes from P388D1 Macrophages and Chinese Hamster Ovary Cells* , 1997, The Journal of Biological Chemistry.

[86]  E. Dennis,et al.  Ca(2+)-independent cytosolic phospholipase A2 from macrophage-like P388D1 cells. Isolation and characterization. , 1994, The Journal of biological chemistry.